Harnessing SARS-CoV-2 immunity to promote antitumor responses through intratumoral vaccination and adoptive transfer
Together, these findings provide proof-of-concept that intratumoral administration of SARS-CoV-2 vaccines can promote antitumor effects through local immune activation in the context of pre-existing antiviral immunity. This strategy may offer a translatable approach for enhancing intratumoral immunotherapy in the post-pandemic era.
Authors
- Mais Eyouni
- Rwaa H. Abdulal
- Manar Darwish
- Rowa Y. Alhabbab (ORCID: https://orcid.org/0000-0001-7135-9967)
- A. M. Hashem
- May A. Alsayb (ORCID: https://orcid.org/0000-0001-8587-1478)
- Tarfa Altorki (ORCID: https://orcid.org/0009-0001-0374-2187)
- Rahaf Alharbi (ORCID: https://orcid.org/0000-0002-9119-8360)
- Mustafa Y. Taher
- Almohanad Alkayyal
- Ahmad Bakur Mahmoud
- Mohammed Yassir Khan
- Haya Hawbani
- Ala A. Azhari
- Rofidah Alsaggaf
- Heba M. Zahid
Institutions
- King Abdulaziz University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Taibah University (SA)
- University of Tabuk (SA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fimmu.2026.1711569
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taibah University
- King Abdulaziz University
- National Institutes of Health